skip to main content

Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus: An Observational Study

Al-Tawfiq, J.A., Momattin, H., Dib, J., and Memish, Z.A. (2014). Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus: An Observational Study. International Journal of Infectious Diseases. 20:42-6.

The authors reviewed the therapeutic schedule and outcomes for five MERS patients who received ribavirin and interferon combination therapy an average of 19 days post-admission. None of the patients responded to therapy and all died, suggesting that this therapy is ineffective in patients with co-morbidities who start treatment late in the course of their illness.
Please Login to Add favorite.
This Article is not Rated. 0-5 Stars Please Login to rate.
You must login to add a comment.